Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALISE: Adalimumab for Sickness Behaviour in RA
NCT05090124Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, single-blind trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoints: Change in sickness score as measured using the sickness questionnaire at Day 42 and Change in brain connectivity as measured by 7T MRI at Day 42. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05090124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090124.